Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Anti-GD2 antibody
Dinutuximab
Unituxin · DIN
Anti-GD2 antibody for high-risk neuroblastoma whose capillary-leak syndrome, hypertension and severe pain are the renal-relevant signals.
ModerateAnti-GD2 immunotherapy era · approved 2015
High-risk neuroblastoma in children achieving at least a partial response to prior multimodality therapy (with GM-CSF, IL-2 and isotretinoin)
Signature kidney injury
Prerenal / Hemodynamic AKI
Severe neuropathic pain is near-universal, and capillary-leak syndrome and hypertension are common, sometimes severe, infusion-associated toxicities (driven partly by concurrent IL-2). The resulting fluid shifts and prerenal AKI are managed proactively but not separately quantified.
Source: Yu et al., N Engl J Med 2010 (ANBL0032)
Mechanism of kidney injury
Anti-GD2 binding activates complement and provokes a strong cytokine response (amplified by co-administered IL-2), producing a capillary-leak syndrome with hypotension, edema and intravascular volume depletion, plus paradoxical hypertension during some infusions. The fluid extravasation and hemodynamic swings cause prerenal azotemia; severe capillary leak can lead to hemodynamic AKI. GD2 is also expressed on peripheral nerves, explaining the severe neuropathic pain (an on-target effect), which is not itself renal but drives opioid use and immobility.
Clinical presentation
Severe infusion-related abdominal/extremity pain requiring opioids, hypotension or hypertension, capillary leak with edema and third-spacing, fever; a prerenal creatinine rise from intravascular depletion. Electrolyte shifts may accompany fluid management.
Onset
Infusion-associated and acute — pain, capillary leak and blood-pressure swings occur during/around each infusion.
Reversibility
Reversible
Anticancer mechanism
Chimeric monoclonal antibody against the disialoganglioside GD2, highly expressed on neuroblastoma. It triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity; given with GM-CSF, IL-2 and isotretinoin it improves survival in high-risk neuroblastoma after consolidation.
Management
Aggressive supportive care: opioid analgesia for pain, IV fluids/vasopressors for capillary-leak hypotension, antihypertensives for infusion hypertension, and slowing/holding the infusion for severe reactions. Restore effective circulating volume to reverse prerenal AKI. Most renal effects resolve with hemodynamic stabilization between infusions.
Risk factors
- Concurrent IL-2 (amplifies capillary leak)
- Pre-existing renal or cardiac compromise
- Inadequate pre-hydration or premedication
- High infusion rate
Prevention
- Pre-hydration and careful fluid management around infusions
- Premedication (analgesia/opioids, antihistamines, antipyretics) and slow infusion
- Close blood-pressure and volume monitoring during infusions
- Dose interruption/rate reduction for severe capillary leak or hemodynamic instability
Note · The renal link is indirect — capillary-leak syndrome, hemodynamic swings (hypotension/hypertension) and severe pain (with IL-2 amplification) cause prerenal AKI rather than a direct lesion.
Clinical depth
Renal dose adjustment
No specific renal dose adjustment in labeling (a monoclonal antibody); manage infusion rate and interruptions for capillary leak, pain and hemodynamic instability.
Dialyzability & ESKD dosing
A monoclonal antibody; not dialyzable. ESKD dosing is not established (used in pediatric neuroblastoma).
Differential diagnosis
Distinguish capillary-leak/hemodynamic prerenal AKI (intravascular depletion with edema, responds to volume/pressors) from sepsis and from intrinsic renal injury. The infusion-bound timing and co-administered IL-2 context are key clues.
Monitoring
- Blood pressure and volume status continuously during infusions
- Serum creatinine and electrolytes around treatment
- Pain assessment and analgesic titration
- Signs of capillary leak (edema, weight gain, hypotension)
Key trials & series
- ANBL0032 (Yu, NEJM 2010) — registrational trial defining capillary leak, hypertension and severe pain
Clinical pearls
- Capillary-leak syndrome with hypotension and intravascular depletion is the renal mechanism — support circulating volume.
- Severe neuropathic pain is on-target (GD2 on nerves) and near-universal — pre-emptive opioids are standard.
- Co-administered IL-2 amplifies the capillary leak and hemodynamic swings.
- Blood pressure can swing both ways during infusions; monitor continuously.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIHypertension
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.Yu AL et al. · N Engl J Med 2010 · PMID 20879881Registrational trial defining capillary leak, hypertension and severe pain — the renal-relevant toxicities.PMIDLong-term follow-up of anti-GD2 immunotherapy in high-risk neuroblastoma (ANBL0032).Yu AL et al. · Clin Cancer Res 2021 · PMID 33504555Long-term outcomes/safety confirming the toxicity profile.PMIDDinutuximab beta in high-risk neuroblastoma (SIOPEN): efficacy and safety.Ladenstein R et al. · Lancet Oncol 2018 · PMID 30442501European experience characterizing capillary leak and pain.PMIDAnti-GD2 monoclonal antibodies in the treatment of neuroblastoma.Perez Horta Z et al. · Immunotherapy 2016 · PMID 27485082Mechanistic review of complement/cytokine-driven toxicity.PMIDPain management during anti-GD2 immunotherapy in neuroblastoma.Mastrangelo S et al. · Cancers (Basel) 2021 · PMID 34884452Management of the severe on-target pain that drives supportive care.PMIDManagement of dinutuximab-associated toxicities in neuroblastoma.Amoroso L et al. · Target Oncol 2025 · PMID 39907793Practical management of capillary leak, hypertension and pain.
Related agents
Other agents sharing the same signature kidney injury.